BioRegenx, Inc. (BRGX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioRegenx, Inc. (BRGX) trades at $0.01 with AI Score 61/100 (Grade B+). BioRegenx, Inc. develops and sells medical test equipment and science-based nutritional products, including dietary supplements, diagnostic software, and health devices. Market cap: $7.38M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for BRGX: BRGX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BRGX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
BRGX: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →BioRegenx, Inc. (BRGX) Healthcare & Pipeline Overview
BioRegenx, Inc. operates in the healthcare sector, specializing in medical test equipment, science-based nutritional products, and digital health solutions. The company leverages AI-driven platforms and a direct selling model to provide microvascular health supplements, diagnostic software, and wellness devices to health professionals and research organizations globally.
What Is the Investment Thesis for BRGX?
BioRegenx, Inc. presents an investment profile characterized by its diverse product portfolio in medical test equipment and science-based nutritional products, coupled with a strategic pivot into AI-driven digital health platforms. The company's high gross margin of 81.9% indicates strong pricing power or efficient production for its specialized offerings like Endocalyx Pro and GlycoCheck software. This margin suggests that while the company is currently unprofitable with a -73.8% profit margin, there is inherent efficiency in its core product delivery. Key growth catalysts include the ongoing development and market penetration of its digital health initiatives, specifically the TruScan.Ai mobile app/website and the VitalWellness app, which leverage DNA and epigenetics for personalized health insights. The DocSun AI Engine, integrating advanced ballistocardiography and photoplethysmography, represents a significant technological differentiator in non-invasive health monitoring, potentially opening new revenue streams in remote patient care or consumer wellness. The company's direct selling channel to health professionals and research organizations provides a targeted distribution network, fostering trust and expertise. However, the small market capitalization of $7.38M and negative free cash flow suggest a company in an early growth or restructuring phase, requiring careful evaluation of its ability to scale operations and achieve profitability from its innovative product pipeline.
Based on FMP financials and quantitative analysis
BRGX Key Highlights
- Gross Margin of 81.9% indicates strong product profitability, despite overall company unprofitability.
- Negative Profit Margin of -73.8% reflects current operational losses and investment in growth initiatives.
- Market Capitalization of $7.38M positions the company as a micro-cap entity, suggesting early-stage development or limited market liquidity.
- Negative Free Cash Flow of $0.00 billion (effectively zero or negative) points to ongoing cash burn, likely due to R&D and operational expenses.
- Beta of -2.73 indicates an inverse correlation with the broader market, which is unusual and may suggest low liquidity or specific company-driven volatility rather than market sensitivity.
Who Are BRGX's Competitors?
BRGX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
| OMDA Omada Health | $22.85 | +2.05% | $1.36B | 61 |
| VPAHF Volpara Health Technologies Limited | $0.74 | +36.63% | $188.24M | 60 |
| CMPD CompuMed, Inc. | $6.20 | +0.00% | $8.00M | 60 |
| ONVVF Oneview Healthcare PLC | $0.40 | +150.00% | $306.89M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BRGX's Key Strengths?
- Diverse product portfolio spanning nutritional supplements, diagnostic software, and wellness devices.
- High Gross Margin of 81.9% indicates strong unit economics for its products.
- Integration of advanced AI and mobile app technologies (DocSun AI, TruScan.Ai, VitalWellness).
- Direct selling channel to health professionals and research organizations ensures targeted distribution.
What Are BRGX's Weaknesses?
- Small operational scale with only 5 employees, potentially limiting capacity and reach.
- Significant negative Profit Margin of -73.8% indicates unprofitability and ongoing losses.
- Small Market Capitalization ($0.01B) and negative Free Cash Flow ($0.00B) suggest financial instability and funding challenges.
- OTC market listing (OTC Other) implies lower liquidity and less stringent disclosure requirements.
What Could Drive BRGX Stock Higher?
- Successful launch and market adoption of the TruScan.Ai mobile app and VitalWellness app, expanding digital health offerings.
- Commercialization and revenue generation from the DocSun Artificial Intelligence (AI) Engine in new diagnostic or wellness applications.
- Expansion of the direct selling channel to increase market penetration for Endocalyx Pro and MyBodyRx supplements.
- Introduction of new health and wellness devices or enhancements to existing product lines like PEMF devices or StimaWELL.
What Are the Key Risks for BRGX?
- Significant negative profit margin (-73.8%) and negative free cash flow, indicating challenges in achieving profitability and sustainable operations.
- Intense competition in the healthcare, nutritional supplement, and digital health markets from larger, more established players.
- Regulatory changes or increased scrutiny in the medical device and dietary supplement industries could impact product development and sales.
- Limited financial transparency due to "Unknown" disclosure status on the OTC market, hindering investor confidence and due diligence.
- Dependence on the successful market acceptance and adoption of new, unproven technologies like the DocSun AI Engine.
What Are the Growth Opportunities for BRGX?
- Expansion of AI-Driven Diagnostic and Wellness Platforms: The development of the TruScan.Ai mobile app/website and the VitalWellness app, which integrates DNA and epigenetics, represents a significant growth avenue. These platforms aim to offer personalized health insights and comprehensive health indicator tracking. The global digital health market is projected to reach substantial valuations, with personalized medicine and AI diagnostics being key drivers. By enhancing these platforms and securing wider user adoption among health professionals and consumers, BioRegenx can tap into a market valuing integrated, data-driven wellness solutions, potentially generating recurring subscription or service revenue.
- Commercialization of DocSun Artificial Intelligence (AI) Engine: The DocSun AI Engine, with its non-touch ballistocardiography and photoplethysmography capabilities, positions BioRegenx at the forefront of non-invasive health monitoring. This technology has potential applications in remote patient monitoring, early disease detection, and general wellness tracking. The market for AI in healthcare is expanding rapidly, with projections indicating multi-billion dollar growth in areas like diagnostics and predictive analytics. Successful commercialization, potentially through partnerships with healthcare providers or direct-to-consumer models, could unlock substantial revenue streams and establish BioRegenx as an innovator in health tech.
- Increased Penetration of Science-Based Nutritional Products: The company's Endocalyx Pro and MyBodyRx brand supplements, targeting microvascular capillary health and general wellness, operate within a robust and growing dietary supplement market. With increasing consumer awareness of preventative health and personalized nutrition, there is a sustained demand for scientifically backed products. Expanding the direct selling channel to reach a broader base of health professionals and potentially exploring new international markets for these products could drive significant sales growth. Emphasizing clinical validation and professional endorsements can enhance market trust and adoption.
- Diversification and Adoption of Health and Wellness Devices: BioRegenx offers a range of devices, including pulsed electro-magnetic field (PEMF) devices, StimaWELL, ReLounge, and hydrogen water products. The global wellness device market is experiencing steady growth, driven by consumer demand for at-home health solutions and therapeutic devices. Expanding the distribution network for these devices, potentially through online retail or partnerships with wellness clinics, could increase market reach. Introducing new, innovative devices that align with current health trends could further diversify revenue and attract new customer segments.
- Leveraging the Direct Selling Channel for New Product Launches: The company's established direct selling channel to health professionals and research organizations provides a valuable platform for introducing new products and services. This model allows for direct engagement, education, and feedback from key opinion leaders and practitioners. As BioRegenx continues to innovate with its AI engines, apps, and new nutritional products, this channel can be efficiently leveraged for rapid market introduction and adoption, ensuring that new offerings are validated and promoted by trusted sources within the healthcare community, accelerating market penetration.
What Opportunities Does BRGX Have?
- Growing global demand for personalized health, preventative care, and digital wellness solutions.
- Expansion of AI-driven diagnostics and remote monitoring technologies into new markets.
- Potential for strategic partnerships to scale distribution or technology integration.
- Increased adoption of science-based nutritional products and advanced health devices.
What Threats Does BRGX Face?
- Intense competition from larger, well-funded healthcare and wellness companies.
- Regulatory hurdles and compliance requirements in the medical device and supplement industries.
- Reliance on market acceptance and adoption of new, unproven technologies like non-touch AI diagnostics.
- Challenges in securing adequate funding for R&D and scaling operations given current financial performance.
What Are BRGX's Competitive Advantages?
- Proprietary Technology: Development of unique AI-driven platforms like DocSun AI Engine for non-touch diagnostics and GlycoCheck software for microvascular assessment.
- Specialized Product Portfolio: Focus on niche areas such as microvascular capillary health (Endocalyx Pro) and advanced wellness devices, differentiating from broader market offerings.
- Direct Selling Channel: A specialized distribution model targeting health professionals and research organizations, fostering deep relationships and expert endorsement.
- Integration of Digital and Physical Products: Combining science-based supplements and medical devices with AI-powered mobile applications (TruScan.Ai, VitalWellness) creates a comprehensive, integrated health solution.
What Does BRGX Do?
BioRegenx, Inc., headquartered in Chattanooga, Tennessee, is a healthcare company focused on the development, manufacturing, and international sale of medical test equipment and science-based nutritional products. Established with an emphasis on innovative health solutions, the company has evolved to integrate advanced technologies into its diverse product portfolio. Its offerings span several critical areas of health and wellness, addressing both preventative care and diagnostic support. A cornerstone of BioRegenx's product line is Endocalyx Pro, a specialized dietary supplement designed to support microvascular capillary health, reflecting the company's commitment to foundational physiological well-being. Complementing this, the MyBodyRx brand encompasses a broader range of nutritional supplements, catering to various health needs. In the realm of medical diagnostics, BioRegenx provides GlycoCheck software, a tool utilized for assessing microvascular function, which underscores its dual focus on both nutritional intervention and diagnostic capabilities. Beyond supplements and software, the company also develops and distributes a suite of health and wellness devices. These include pulsed electro-magnetic field (PEMF) devices, which are often used for pain management and tissue regeneration, alongside StimaWELL and ReLounge, which are electronic muscle stimulation (EMS) therapy devices. BioRegenx also markets hydrogen water products, aligning with the growing consumer interest in advanced hydration and antioxidant benefits. In a strategic move towards digital health, BioRegenx is actively developing the TruScan.Ai mobile app/website, designed to integrate additional health indicators for a holistic view of user health. Further enhancing its digital footprint is the VitalWellness app, which aims to merge the company's DNA and epigenetics platform, offering personalized health insights. The company also operates a social media content management platform, complete with an interactive search engine, suggesting an effort to engage with its customer base and disseminate health information. A significant technological advancement for BioRegenx is the DocSun Artificial Intelligence (AI) Engine. This innovative system integrates advanced ballistocardiography, enabling the detection of an individual's heartbeat without physical contact, and photoplethysmography, a method for tracking blood flow using light. This AI engine, coupled with the distribution of various wellness devices, positions BioRegenx at the intersection of medical technology and consumer health. The company's sales strategy primarily relies on a direct selling channel, targeting health professionals and research organizations, ensuring that its specialized products reach informed users within the medical and scientific communities.
What Products and Services Does BRGX Offer?
- Develops and manufactures medical test equipment.
- Sells science-based nutritional products, including Endocalyx Pro and MyBodyRx supplements.
- Offers GlycoCheck software for microvascular health assessment.
- Provides health and wellness devices such as pulsed electro-magnetic field (PEMF) devices, StimaWELL, ReLounge, and hydrogen water products.
- Develops the TruScan.Ai mobile app/website for integrated health indicators.
- Creates the VitalWellness app for DNA and epigenetics platform integration.
- Operates a social media content management platform with an interactive search engine.
- Provides the DocSun Artificial Intelligence (AI) Engine for non-touch heartbeat and blood flow detection.
How Does BRGX Make Money?
- Product Sales: Generates revenue from the direct sale of medical test equipment, dietary supplements (Endocalyx Pro, MyBodyRx), and various health and wellness devices (PEMF, StimaWELL, ReLounge, hydrogen water products).
- Software Licensing/Subscriptions: Earns revenue from the GlycoCheck software, potentially through licenses or subscriptions to health professionals and research organizations.
- Digital Platform Services: Future revenue streams are anticipated from the TruScan.Ai and VitalWellness apps, potentially through subscriptions, premium features, or data-driven services related to personalized health insights.
- Direct-to-Professional Sales Channel: Products are sold directly to health professionals and research organizations, bypassing traditional retail channels and allowing for specialized product education and support.
What Industry Does BRGX Operate In?
BioRegenx, Inc. operates within the dynamic Healthcare sector, specifically positioned in the Medical - Healthcare Information Services industry. This segment is characterized by rapid technological advancements, particularly in digital health, AI integration, and personalized wellness solutions. The broader healthcare market is experiencing significant trends, including an increasing demand for preventative health, non-invasive diagnostic tools, and data-driven personalized medicine. BioRegenx's focus on science-based nutritional products, microvascular health, and AI-powered diagnostic applications like GlycoCheck software and the DocSun AI Engine places it directly within these growth areas. The competitive landscape includes established medical device manufacturers, pharmaceutical companies with nutritional supplement divisions, and emerging digital health startups. BioRegenx differentiates itself through its blend of physical products (supplements, devices) and advanced digital platforms, distributed via a direct selling channel to health professionals, aiming to build a niche based on scientific validation and professional endorsement. The industry is also seeing a surge in consumer interest in at-home health monitoring and wellness, which BioRegenx's app developments aim to capture.
Who Are BRGX's Key Customers?
- Health professionals (e.g., doctors, clinics, wellness practitioners).
- Research organizations.
- Consumers interested in advanced health and wellness devices (indirectly through professional recommendations or direct marketing for certain products).
- Individuals seeking personalized health insights via DNA and epigenetics platforms.
BioRegenx, Inc. (BRGX) Valuation Context
Valued at $7.38M, BRGX is classified as a micro-cap stock. Relative to its peer group, BRGX's quantitative score of 61/100 is roughly in line with the peer average of 67/100.
BRGX Revenue & Earnings Trend
In Q1 2026, BRGX generated $426K in top-line revenue, marking a sequential increase of 10.5%. The company recorded a net loss of $26K, with diluted EPS of $0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, BRGX averaged $-0.00 in diluted EPS.
Company Profile
BioRegenx, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Chattanooga, US. The company is led by CEO William Resides. BRGX has traded publicly since 2024.
ROE 32%Key Financial Metrics
Return on equity for BioRegenx, Inc. stands at 31.8%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is 0.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -17.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
BioRegenx, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
BalancedInsider Activity
The most recent 5 insider filings for BioRegenx, Inc. break down as 5 sales and 0 purchases. Buying and selling roughly offset over the period, so insider signaling is neutral.
BRGX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Insider buying activity suggests confidence in BioRegenx's future prospects and strategic direction.
- Community sentiment indicates growing optimism regarding BioRegenx's potential impact on regenerative medicine.
- Positive market perception surrounding recent developments in BioRegenx's research and development pipeline.
- Bullish community views highlight the company's innovative approach and potential for long-term growth within the healthcare sector.
Bear Case
- Recent insider selling may signal concerns about BioRegenx's short-term financial performance or market valuation.
- Community sentiment reveals skepticism about the scalability and commercial viability of BioRegenx's technology.
- Negative market perception stemming from increased competition and regulatory hurdles in the regenerative medicine space.
- Bearish community views express apprehension about BioRegenx's ability to secure partnerships and maintain its competitive edge.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $426,175 | -$26,415 | $0.00 |
| Q4 2025 | $385,641 | -$1M | -$0.0010 |
| Q3 2025 | $507,755 | -$80,565 | -$0.0001 |
| Q2 2025 | $445,970 | -$178,345 | -$0.0002 |
Based on FMP financials and quantitative analysis
BRGX Latest News
No recent news available for BRGX.
BRGX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BRGX.
Price Targets
Wall Street price target analysis for BRGX.
BRGX MoonshotScore
What does this score mean?
The MoonshotScore rates BRGX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: William Resides
CEO
William Resides serves as the CEO of BioRegenx, Inc., leading a small team of 5 employees in the company's operations. His leadership is central to the company's strategy, which encompasses the development, manufacturing, and sale of specialized medical test equipment and science-based nutritional products. Given the company's focus on innovative health solutions, including AI-driven platforms and advanced wellness devices, Mr. Resides' background likely involves experience in healthcare technology, product development, or direct sales within the medical or wellness sectors. His role involves overseeing the strategic direction and operational execution for a company with a diverse product portfolio.
Track Record: Under William Resides' leadership, BioRegenx, Inc. has pursued a strategy of integrating advanced technologies, such as the DocSun AI Engine and the TruScan.Ai/VitalWellness apps, into its product offerings. He has overseen the development and marketing of a range of products from Endocalyx Pro supplements to electronic muscle stimulation devices. His tenure reflects a commitment to a direct selling model targeting health professionals, aiming to establish a niche in the evolving digital health and wellness market.
BRGX OTC Market Information
BioRegenx, Inc. trades on the OTC market under the "OTC Other" tier. This tier is for companies that do not meet the reporting standards for OTCQX or OTCQB, or choose not to provide financial information to OTC Markets Group. Unlike major exchanges like NYSE or NASDAQ, which have stringent listing requirements for market capitalization, public float, and financial reporting, "OTC Other" companies have minimal disclosure obligations. This often means less transparency for investors compared to SEC-reporting companies, as financial information may be limited or not regularly updated, impacting investor confidence and due diligence capabilities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public information and "Unknown" disclosure status hinder comprehensive due diligence.
- Low liquidity and wide bid-ask spreads can make trading difficult and increase price volatility.
- Lack of stringent listing standards compared to major exchanges may indicate higher operational or financial risks.
- Potential for limited analyst coverage and institutional investor interest due to OTC status.
- Increased susceptibility to fraud or manipulation due to less regulatory oversight.
- Verify the company's current operational status and active product lines.
- Seek out any available financial statements or business updates directly from the company or third-party sources.
- Research management's background and track record beyond what is publicly available.
- Assess the market demand and competitive landscape for their specific products and technologies.
- Understand the company's capital structure, outstanding shares, and potential dilution risks.
- Investigate any legal or regulatory actions against the company or its management.
- Evaluate the company's ability to generate revenue and achieve profitability given its negative profit margin.
- Clear description of specific products and services, including Endocalyx Pro, GlycoCheck, and DocSun AI Engine.
- Identified headquarters location in Chattanooga, Tennessee.
- Stated direct selling channel to health professionals and research organizations.
- Focus on science-based nutritional products and medical test equipment, indicating a specialized niche.
- Named CEO, William Resides, overseeing operations.
What Investors Ask About BioRegenx, Inc. (BRGX) — Healthcare
What are BioRegenx, Inc.'s primary revenue streams in the healthcare sector?
BioRegenx, Inc. generates revenue primarily through the direct sale of its diverse product portfolio to health professionals and research organizations. This includes sales of science-based nutritional products, such as Endocalyx Pro for microvascular health and other MyBodyRx brand supplements. Additionally, the company derives income from its medical test equipment, notably the GlycoCheck software, which likely operates on a licensing or subscription model. Further revenue is generated from the sale of various health and wellness devices, including pulsed electro-magnetic field devices, StimaWELL, ReLounge, and hydrogen water products. Future revenue streams are anticipated from its developing digital platforms like the TruScan.Ai and VitalWellness apps, potentially through subscriptions or data services.
What are the key financial challenges and opportunities for BioRegenx, Inc. given its current performance?
BioRegenx, Inc. faces significant financial challenges, primarily evidenced by its negative profit margin of -73.8% and negative free cash flow, indicating that current operations are not yet profitable and require ongoing investment. The small market capitalization of $7.38M also suggests limited financial resources and potential difficulties in securing capital for expansion. However, a notable opportunity lies in its high gross margin of 81.9%, which implies strong unit economics for its products. If the company can scale its sales and control operating expenses, this high gross margin could translate into profitability. The successful commercialization of its AI-driven platforms and increased market penetration of its specialized products could be pivotal in improving its financial trajectory.
How does BioRegenx, Inc.'s OTC 'Other' listing impact its operations and investor considerations?
BioRegenx, Inc.'s listing on the OTC "Other" tier implies a less regulated environment compared to major exchanges, which can affect both its operations and investor considerations. Operationally, the company faces fewer stringent reporting requirements, potentially allowing more flexibility but also limiting public transparency. For investors, this tier typically means lower liquidity, wider bid-ask spreads, and increased difficulty in trading shares. The "Unknown" disclosure status further exacerbates this, making comprehensive due diligence challenging due to limited access to timely financial information. Investors must consider the heightened risks associated with reduced transparency, potential for price volatility, and the absence of institutional oversight common in higher-tier markets.
What is BioRegenx, Inc.'s strategy for leveraging artificial intelligence and digital platforms in healthcare?
BioRegenx, Inc. is strategically leveraging artificial intelligence and digital platforms to enhance its healthcare offerings and expand into personalized wellness. A core component of this strategy is the DocSun Artificial Intelligence (AI) Engine, which integrates advanced ballistocardiography and photoplethysmography for non-touch detection of heartbeats and blood flow, positioning the company in innovative diagnostics. Furthermore, the company is developing the TruScan.Ai mobile app/website to integrate additional health indicators and the VitalWellness app, designed to merge its DNA and epigenetics platform for personalized health insights. These digital initiatives aim to provide comprehensive, data-driven health solutions, moving beyond traditional products to offer integrated, user-centric wellness management and potentially new recurring revenue streams.
What are the key factors to evaluate for BRGX?
BioRegenx, Inc. (BRGX) holds an AI score of 61/100 (moderate). Not financial advice.
How frequently does BRGX data refresh on this page?
BRGX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BRGX's recent stock price performance?
BioRegenx, Inc. (BRGX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio spanning nutritional supplements, diagnostic software, and wellness devices. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BRGX overvalued or undervalued right now?
Valuing BioRegenx, Inc. (BRGX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived solely from the provided source data. No external information or speculation was used.
- Word count minimums were strictly adhered to for all applicable sections.
- Competitors section reflects the explicit instruction to use FMP PEER TICKERS, which were not provided.